The Role and Mechanism of the Histone Methyltransferase G9a in Tumors: Update
DOI: https://doi.org/10.2147/ott.s451108
IF: 4
2024-05-30
OncoTargets and Therapy
Abstract:Hangsheng Zhou, 1, 2, &ast Jiandong Gui, 1, 2, &ast Lijie Zhu, 2 Yuanyuan Mi 2 1 Wuxi Medical College, Jiangnan University, Wuxi, Jiangsu Province, 214122, People's Republic of China; 2 Department of Urology, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu Province, 214122, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yuanyuan Mi; Lijie Zhu, Department of Urology, Affiliated Hospital of Jiangnan University, No. 1000 Hefeng Road, Wuxi, Jiangsu, 214122, People's Republic of China, Email ; Methylation-mediated gene silencing is closely related to the occurrence and development of human tumors. The euchromatic histone lysine methyltransferase 2 (EHMT2, also known as G9a) is highly expressed in many tumors and is generally considered to be an oncogene, which is associated with the poor outcome of many tumors. Combined immunotherapy and immune checkpoint blockade therapy also have good efficacy and certain safety. However, there are still many difficulties in the drugs targeting G9a, and the combined effect and safety of G9a with many drugs is still under study. This article aims to summarize the role and mechanism of G9a and its inhibitors in tumors in the past two years, and to understand the application prospect of G9a from the perspective of diagnosis and treatment. Keywords: cancer, G9a, methyltransferase, function, mechanism Epigenetic regulation is an essential process in human growth and development. Epigenetic modifications allow differential expression of genes in different environments, altering gene functions without changing their sequence. Abnormal DNA methylation, chromatin modifications or remodeling, and dysregulated expression of non-coding RNAs(ncRNA) are hallmarks of cancer. 1 The epigenetic mechanism causes instability in the cancer genome, limits tumor suppressor genes, promotes oncogenic genes, and high methylation at CpG islands is a characteristic of the cancer genome. By adjusting these dysfunctions, tumor suppression can be achieved. 2 Chromatin, a large DNA and histones molecular complex, is a scaffold that packages the entire human genome. Chromatin-modifying enzymes substantially modify and remove DNA and histone modifications in a highly regulated manner. 3 Chromatin remodeling signal transduction can affect DNA damage response and repair, DNA replication stress, aging, metastasis, angiogenesis, and tumor immunity, mainly through histone modification and ATP dependent remodeling agents to achieve its function. It can directly inhibit chromatin remodeling, DNA damage repair, or target genes, proteins, and even genetic defects in the genome. 4 DNA forms chromatin in the eukaryotic cells' nucleus by associating with nuclear proteins. The nucleosome's fundamental structural unit of chromatin comprises 146 DNA base pairs wrapped around core histones H2A, H2B, H3, and H4. 5 Chromatin structure is partially regulated by enzymes that post-translationally modify specific amino acids on histones. These post-translational modifications include acetylation, phosphorylation, poly-ADP-ribosylation, ubiquitination, and methylation. 6 The epigenetic modifications-produced information is essential for all DNA-associated processes, including transcription, repair, and replication. Therefore, abnormal expression patterns or genomic alterations of chromatin regulatory factors may profoundly affect and promote the initiation and maintenance of various cancers. 3 An important marker of epigenetic abnormalities is chronic DNA damage associated with cell stress, present in chronic inflammation and aging processes. This stress may transiently assemble transcriptional repressor complexes crucial for DNA repair at damaged sites. 7 Over 50% of human cancers harbor mutations in enzymes involved in chromatin organization. Tumor cells activate genetic and epigenetic changes and employ epigenetic processes as a routine mechanism to evade chemotherapy and host immune surveillance. Therefore, currently, the drug discovery research's primary target is epigenome, including DNA methylation and histone modifications. 7 Epigenetic processes are also indicated to regulate immune cell function, mediating anti-tumor immunity. Compared to mono-immune-based therapies, co-treatment with epigenetic therapy may overcome certain limitations of current immune treatment strategies. 8 ncRNA regulate gene expression by recruiting chromatin remodeling and modification complexes to specific sites. They can interact with chromatin modifying enzymes and affect chromosome structure by changing their histone modification status. 9 DNMT and 10–7 t -Abstract Truncated-
oncology,biotechnology & applied microbiology